Stratos Wealth Advisors LLC Acquires 1,817 Shares of Danaher Corporation (NYSE:DHR)

Stratos Wealth Advisors LLC increased its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 13.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,707 shares of the conglomerate's stock after acquiring an additional 1,817 shares during the quarter. Stratos Wealth Advisors LLC's holdings in Danaher were worth $3,220,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of DHR. FAS Wealth Partners Inc. increased its stake in Danaher by 20.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after purchasing an additional 1,639 shares in the last quarter. Horizon Financial Services LLC increased its stake in Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after purchasing an additional 8,160 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Danaher by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after purchasing an additional 579,046 shares in the last quarter. Terra Alpha Investments LLC bought a new stake in Danaher during the 4th quarter valued at about $3,068,000. Finally, Rathbones Group PLC increased its stake in Danaher by 2.5% during the 4th quarter. Rathbones Group PLC now owns 319,502 shares of the conglomerate's stock valued at $73,342,000 after purchasing an additional 7,695 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Transactions at Danaher

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president directly owned 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.20% of the company's stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $199.60 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a market capitalization of $142.85 billion, a P/E ratio of 38.76, a P/E/G ratio of 2.85 and a beta of 0.77. The firm's 50 day simple moving average is $195.71 and its two-hundred day simple moving average is $206.90.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Research analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. Danaher's dividend payout ratio (DPR) is 24.85%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. UBS Group reduced their price objective on shares of Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Wolfe Research dropped their price target on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a report on Monday, April 7th. Argus dropped their price target on shares of Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $248.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.